NO20060654L - PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme - Google Patents

PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme

Info

Publication number
NO20060654L
NO20060654L NO20060654A NO20060654A NO20060654L NO 20060654 L NO20060654 L NO 20060654L NO 20060654 A NO20060654 A NO 20060654A NO 20060654 A NO20060654 A NO 20060654A NO 20060654 L NO20060654 L NO 20060654L
Authority
NO
Norway
Prior art keywords
same
group
pharmaceutical composition
composition containing
activating compound
Prior art date
Application number
NO20060654A
Other languages
English (en)
Other versions
NO335823B1 (no
Inventor
Yukiyoshi Yamazaki
Tsutomu Toma
Hidefumi Ozawa
Ayumu Okuda
Masahiro Nishikawa
Takaaki Araki
Kazutoyo Abe
Soichi Oda
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of NO20060654L publication Critical patent/NO20060654L/no
Publication of NO335823B1 publication Critical patent/NO335823B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet en forbindelse for selektiv aktivering av PPARa som er representert ved den generelle formel (1) (hvor R, og R2, som kan være like eller forskjellige, representerer et hydrogenatom eller lignende; R3a, R3b, R4a og R4b, kan være like eller forskjellige, og representerer et hydrogenatom eller lignende; X representerer et oksygenatom eller lignende; Y representerer et oksygenatom, S(O)i (I er tallene 0 til 2), en karbonylgruppe, en karbonylaminogruppe, en aminokarbonylgruppe, en sulfonylaminogruppe eller en NH-gruppe; Z representerer CH eller lignende; n er tallene 1 til 6; og m er tallene 2 til 6) eller et salt derav. Det er også beskrevet et terapeutisk medikament inneholdende en slik forbindelse.
NO20060654A 2003-09-03 2006-02-09 PPAR-aktiverende forbindelse samt anvendelse derav, og terapeutisk medikament inneholdende samme NO335823B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49935703P 2003-09-03 2003-09-03
JP2003317353 2003-09-09
JP2003364817 2003-10-24
PCT/JP2004/012750 WO2005023777A1 (ja) 2003-09-03 2004-09-02 Ppar活性化化合物及びこれを含有する医薬組成物

Publications (2)

Publication Number Publication Date
NO20060654L true NO20060654L (no) 2006-04-26
NO335823B1 NO335823B1 (no) 2015-02-23

Family

ID=34279568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060654A NO335823B1 (no) 2003-09-03 2006-02-09 PPAR-aktiverende forbindelse samt anvendelse derav, og terapeutisk medikament inneholdende samme

Country Status (17)

Country Link
US (2) US7109226B2 (no)
EP (1) EP1661890B1 (no)
JP (2) JP4226005B2 (no)
KR (1) KR101160808B1 (no)
AU (1) AU2004270538C1 (no)
BR (1) BRPI0413991B8 (no)
CA (1) CA2535749C (no)
CY (1) CY1111867T1 (no)
EA (1) EA009374B1 (no)
HR (1) HRP20110009T1 (no)
IL (1) IL173639A (no)
MX (1) MXPA06002435A (no)
NO (1) NO335823B1 (no)
NZ (1) NZ545692A (no)
PL (1) PL1661890T3 (no)
TW (1) TWI324599B (no)
WO (1) WO2005023777A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528375C (en) * 2003-06-18 2013-11-19 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
DE602004030344D1 (de) * 2003-07-31 2011-01-13 Tranzyme Pharma Inc Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
US7398116B2 (en) 2003-08-11 2008-07-08 Veran Medical Technologies, Inc. Methods, apparatuses, and systems useful in conducting image guided interventions
US7301033B2 (en) * 2005-01-27 2007-11-27 Kowa Co., Ltd. PPAR-activating compound
US7790903B2 (en) 2005-02-23 2010-09-07 Kowa Co., Ltd. Process for production of optically active PPAR-activating compound and intermediate of the same
US7538242B2 (en) 2005-03-01 2009-05-26 Kowa Co., Ltd. Optically active PPAR-activating compound intermediate and method for producing same
EP1887005B1 (en) * 2005-05-31 2010-04-21 Kowa Co., Ltd. Processes for production of optically active ppar-activating compounds and intermediates for production thereof
WO2007013555A1 (ja) 2005-07-28 2007-02-01 Kowa Co., Ltd. 光学活性2-ヒドロキシ酪酸エステルの製造法
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
JP5679458B2 (ja) * 2009-09-28 2015-03-04 興和株式会社 内臓脂肪重量の低下剤
TWI425948B (zh) * 2012-01-20 2014-02-11 優生生物科技股份有限公司 Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases
EA024873B1 (ru) 2012-09-27 2016-10-31 Кова Компани, Лтд. Терапевтическое средство при дислипидемии
JP5734533B2 (ja) * 2013-03-29 2015-06-17 興和株式会社 2−ヒドロキシカルボン酸又はその誘導体の光学純度向上法
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
KR20240152981A (ko) 2013-08-28 2024-10-22 교와 가부시키가이샤 지질 이상증 치료제
EP3091970B1 (en) * 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
TW201618777A (zh) * 2014-09-26 2016-06-01 興和股份有限公司 脂質異常症治療劑
WO2017082393A1 (ja) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 緑内障予防治療剤
PT3275438T (pt) 2016-07-29 2021-01-25 Kowa Co Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual
WO2018037593A1 (ja) * 2016-08-25 2018-03-01 興和株式会社 Pbcの治療剤
JP2019059673A (ja) * 2016-08-25 2019-04-18 興和株式会社 Pbcの治療剤
JP7202892B2 (ja) 2017-01-11 2023-01-12 興和株式会社 非アルコール性脂肪性肝疾患の予防及び治療薬
US10314825B2 (en) 2017-02-24 2019-06-11 Kowa Company, Ltd. Agent for treatment of PBC
CN110831591A (zh) 2017-06-30 2020-02-21 兴和株式会社 医药组合物
US20200129483A1 (en) * 2017-06-30 2020-04-30 Kowa Company, Ltd. Pharmaceutical composition
JP7425603B2 (ja) * 2017-06-30 2024-01-31 興和株式会社 医薬組成物
EP3646864B1 (en) 2017-06-30 2026-04-08 Kowa Company, Ltd. Pharmaceutical containing pemafibrate
KR20200021481A (ko) * 2017-06-30 2020-02-28 교와 가부시키가이샤 의약품
WO2019004448A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
JPWO2019004452A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
JPWO2019004447A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
EP4696381A3 (en) 2017-06-30 2026-04-22 Kowa Company, Ltd. Medicine
JP6959049B2 (ja) * 2017-06-30 2021-11-02 興和株式会社 新規低アルブミン血症改善薬
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
SG11202005850VA (en) * 2017-12-21 2020-07-29 Kowa Co Methods of treatment of hypertrigl yceridemia
WO2019133462A1 (en) 2017-12-27 2019-07-04 Teva Pharmaceuticals International Gmbh Solid state forms of pemafibrate
JP7356968B2 (ja) 2018-05-08 2023-10-05 国立大学法人 岡山大学 心血管疾患に有用な医薬
WO2020138407A1 (ja) * 2018-12-27 2020-07-02 興和株式会社 医薬品
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物
EP3903782A4 (en) 2018-12-27 2022-10-05 Kowa Company, Ltd. PHARMACEUTICAL COMPOSITION
WO2020138405A1 (ja) 2018-12-27 2020-07-02 興和株式会社 医薬品
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof
AU2022262535A1 (en) 2021-04-20 2023-11-16 Kowa Company, Ltd. Combination medicine for preventing/treating dyslipidemia or cardiovascular disease
CA3216699A1 (en) * 2021-04-28 2022-11-03 Kowa Company, Ltd. Blood carnitine-increasing agent
CN118946357A (zh) 2022-03-31 2024-11-12 学校法人慈惠大学 呼吸系统疾病治疗剂
WO2024010030A1 (ja) 2022-07-06 2024-01-11 興和株式会社 血中マイオスタチン低下剤
WO2024014524A1 (ja) 2022-07-15 2024-01-18 興和株式会社 血中ldlコレステロール低下剤
WO2024201358A1 (en) * 2023-03-31 2024-10-03 Ami Lifesciences Private Limited A process for the preparation of pemafibrate and intermediates thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025425B2 (ja) * 1975-03-06 1985-06-18 藤沢薬品工業株式会社 置換フエノキシ脂肪酸類の合成法
JPS593465B2 (ja) * 1974-06-04 1984-01-24 藤沢薬品工業株式会社 チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO2002046176A1 (en) * 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Ppar (peroxisome proliferator activated receptor) activators
DE10151390A1 (de) * 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
EP1480957A1 (en) * 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
MXPA06002435A (es) 2006-06-20
US7109226B2 (en) 2006-09-19
US20050101636A1 (en) 2005-05-12
AU2004270538B2 (en) 2009-07-16
EP1661890A1 (en) 2006-05-31
EA009374B1 (ru) 2007-12-28
NO335823B1 (no) 2015-02-23
US7183295B2 (en) 2007-02-27
AU2004270538A1 (en) 2005-03-17
TW200524884A (en) 2005-08-01
CA2535749C (en) 2011-11-01
US20060189667A1 (en) 2006-08-24
BRPI0413991B8 (pt) 2021-05-25
PL1661890T3 (pl) 2011-06-30
EP1661890B1 (en) 2011-01-05
NZ545692A (en) 2009-02-28
JPWO2005023777A1 (ja) 2007-11-01
HK1093975A1 (zh) 2007-03-16
BRPI0413991B1 (pt) 2018-09-18
CY1111867T1 (el) 2015-11-04
WO2005023777A1 (ja) 2005-03-17
CA2535749A1 (en) 2005-03-17
JP4226005B2 (ja) 2009-02-18
TWI324599B (en) 2010-05-11
BRPI0413991A (pt) 2006-11-07
JP2009114185A (ja) 2009-05-28
IL173639A0 (en) 2006-07-05
AU2004270538C1 (en) 2010-01-14
EA200600527A1 (ru) 2006-08-25
JP4931893B2 (ja) 2012-05-16
KR20060119890A (ko) 2006-11-24
IL173639A (en) 2010-12-30
KR101160808B1 (ko) 2012-06-29
EP1661890A4 (en) 2008-12-03
HRP20110009T1 (hr) 2011-03-31

Similar Documents

Publication Publication Date Title
EP1661890A4 (en) PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
BG108089A (en) Pyridine matrix metalloproteinase inhibitors
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20083026L (no) Terapeutisk middel for diabetes
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
WO2001083459A3 (en) Uracil substituted phenyl sulfamoyl carboxamides
NO20011351L (no) Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav
DK1483246T3 (da) 5-Substituerede alkylaminopyrazolderivater som pesticider
NO20070570L (no) Forbindelser.
WO2005097788A3 (en) Sulfonamides and uses thereof
NO20060426L (no) Kannabinoid reseptormodulator
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
NO20083790L (no) Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
DE602004029355D1 (de) Sulfopyrrolderivate
NO20043211L (no) Imidazo [1,2-a]pyridinderivat
NO20071616L (no) Benzoksazin- og kinoksalinderivater og anvendelser
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
NO20002575L (no) Substituerte oksimer som neurokininantagonister
BRPI0409951A (pt) derivados de anilina, sua produção e uso como agentes farmacêuticos
DE60227008D1 (de) Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen
RU94033470A (ru) Циклогексановые производные, фармкомпозиция на их основе и способ лечения

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees